Oxford Science Enterprises

Oxford Science EnterprisesOxford Science Enterprises
Oxford Science Enterprises

Oxford Science Enterprises

Independent investment company and venture builder partnering with the University of Oxford to build businesses.

DR 482015ActiveOxford, United Kingdom
Rate

About

Oxford Science Enterprises is an independent investment company and venture builder that transforms cutting-edge scientific research from the University of Oxford into transformational businesses. It focuses on early-stage investments across life sciences, health tech, and deep tech, providing capital, operational expertise, and infrastructure to help spinouts scale.
Frequently asked

What does Oxford Science Enterprises do?

Oxford Science Enterprises is an independent investment company and venture builder that transforms cutting-edge scientific research from the University of Oxford into transformational businesses. It focuses on early-stage investments across life sciences, health tech, and deep tech, providing capital, operational expertise, and infrastructure to help spinouts scale.

What is Oxford Science Enterprises's revenue?

StartupHub estimates Oxford Science Enterprises's annual revenue at $152.4M (range $36.3M to $226.0M, 27% confidence), based on comparable companies in the sector.

What is Oxford Science Enterprises's valuation?

StartupHub estimates Oxford Science Enterprises's effective valuation at $2.1B (range $1.3B to $3.2B, 17% confidence), based on comparable companies in the sector.

How much funding has Oxford Science Enterprises raised?

Oxford Science Enterprises has raised a total of $532M in funding. The most recent round on record is Bridge.

Where is Oxford Science Enterprises headquartered?

Oxford Science Enterprises is headquartered in Oxford, United Kingdom.

When was Oxford Science Enterprises founded?

Oxford Science Enterprises was founded in 2015.

What industry does Oxford Science Enterprises operate in?

Oxford Science Enterprises operates in Life Sciences, HealthTech, Deep Tech, Venture Capital.

Comments

No comments yet. Be the first to share your take.